IFN from the regimens, thus reducing the risk of
serious psychiatric complications that are a concern
of both patients and their healthcare providers
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Ghany MG NDSDTDSL, American Association for Study of Liver
Diseases. An update on treatment of genotype 1 chronic hepatitis C
virus infection: 2011 practice guideline by the American Association
for the Study of Liver Diseases. Hepatology 2014;54(4):1433-1444.
Hepatitis B and C. Food and Drug Administration 2014 February
14;Available at: URL: http://www.fda.gov/ForConsumers/
ByAudience/ForPatientAdvocates/ucm151488.htm. Accessed
February 17, 2014.
Gaetano JN, Reau N. Hepatitis C: management of side effects
in the era of direct-acting antivirals. Curr Gastroenterol Rep
2013;15(1):305.
(4) Rodriguez-Torres M. Focus on drug interactions: the challenge of
treating hepatitis C virus infection with direct-acting antiviral drugs in
the HIV-positive patient. Curr Opin Infect Dis 2013;26(1):50-57.
Backx M, Lewszuk A, White JR et al. The cost of treatment failure:
resource use and costs incurred by hepatitis C virus genotype
1-infected patients who do or do not achieve sustained virological
response to therapy. J Viral Hepat 2014;21(3):208-215.
Aghemo A, De FR. New horizons in hepatitis C antiviral therapy with
direct-acting antivirals. Hepatology 2013;58(1):428-438.
Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily
simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive
hepatitis C genotype 1-infected patients in Japan: the DRAGON
study. J Gastroenterol 2014;49(1):138-147.
Sovaprevir HCV NS3/4A Protease Inhibitor. Achillion
Pharmaceuticals 2014 January 1;Available at: URL: http://www.
achillion.com/sovaprevir_ACH1625. Accessed February 17, 2014.
Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated
assessment from European Medicines Agency. Boehringer Ingelheim
2013 November 26;Available at: URL: http://www.boehringeringelheim.com/news/news_releases/press_releases/2013/26_
november_2013hcv.html. Accessed February 17, 2014.
Sulkowski MS, Bourliere M, Bronowicki JP et al. Faldaprevir
combined with peginterferon alfa-2a and ribavirin in chronic hepatitis
C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Hepatology 2013;57(6):2155-2163.
Bronowicki JP, Pol S, Thuluvath PJ et al. Randomized study
of asunaprevir plus pegylated interferon-alpha and ribavirin for
previously untreated genotype 1 chronic hepatitis C. Antivir Ther
2013;18(7):885-893.
Everson GT, Sims KD, Rodriguez-Torres M et al. Efficacy of an
Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir,
and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1
Infection. Gastroenterology 2014;146(2):420-429.
Everson G, Cooper C, Hezode C et al. DAUPHINE: a randomized
phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/
ribavirin in HCV genotypes 1 or 4. Liver Int 2014.
Gane EJ, Rouzier R, Wiercinska-Drapalo A et al. Efficacy and
Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a-Ribavirin
in Hepatitis C Virus Genotype 1 Prior Null Responders. Antimicrob
Agents Chemother 2014;58(2):1136-1145.
Merck Announces Presentation of Interim Data fr